









Markets
/
Stocks
/
nasdaq-ptct
/

PTC Therapeutics Inc

PTCT

71.770USD

+4.050+5.98%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

5.74BMarket Cap

9.12P/E TTM



PTC Therapeutics Inc

71.770

+4.050+5.98%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of PTC Therapeutics Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PTC Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

14 / 159

Overall Ranking

47 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 17 analysts

Buy

Current Rating

68.733

Target Price

+1.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

PTC Therapeutics Inc Highlights

StrengthsRisks

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 15.45% year-on-year.

Overvalued

The company’s latest PE is 8.48, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 79.84M shares, decreasing 10.81% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 63.00K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 8.57, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 178.88M, representing a year-over-year decrease of 4.19%, while its net profit experienced a year-over-year decrease of 34.61%.

Score

Industry at a Glance

Previous score

8.57

Change



Financials

7.54

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.05

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.71

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.57

Key Metrics

Free cash flow

No Data

PTC Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.42, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 8.48, which is 1.17% below the recent high of 8.58 and 242.56% above the recent low of -12.09.

Score

Industry at a Glance

Previous score

8.42

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 14/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 7.65, which is lower than the Pharmaceuticals industry's average of 7.77. The average price target for PTC Therapeutics Inc is 70.00, with a high of 118.00 and a low of 44.00.

Score

Industry at a Glance

Previous score

7.65

Change

Support & Resistance

No Data

Analyst Rating

Based on 17 analysts

Buy

Current Rating

77.313

Target Price

+14.16%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

PTC Therapeutics Inc

PTCT

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 8.55, which is higher than the Pharmaceuticals industry's average of 6.89. Sideways: Currently, the stock price is trading between the resistance level at 70.63 and the support level at 64.06, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.82

Change

-0.27

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

-0.065

Neutral

RSI(14)

72.428

Buy

STOCH(KDJ)(9,3,3)

62.719

Buy

ATR(14)

2.479

High Vlolatility

CCI(14)

299.369

Overbought

Williams %R

23.605

Buy

TRIX(12,20)

0.383

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

68.768

Buy

MA10

67.896

Buy

MA20

67.334

Buy

MA50

62.412

Buy

MA100

55.635

Buy

MA200

52.345

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 100.51%, representing a quarter-over-quarter decrease of 4.99%. The largest institutional shareholder is The Vanguard, holding a total of 8.29M shares, representing 10.43% of shares outstanding, with 11.52% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

8.83M

+2.75%

RTW Investments L.P.

7.75M

+3.52%

BlackRock Institutional Trust Company, N.A.

5.79M

-2.66%

Armistice Capital LLC

4.74M

-12.87%

Wellington Management Company, LLP

4.69M

-13.38%

Janus Henderson Investors

3.18M

+8.86%

State Street Investment Management (US)

3.00M

+22.06%

TD Securities, Inc.

2.45M

-6.40%

D. E. Shaw & Co., L.P.

2.44M

+68.67%

Geode Capital Management, L.L.C.

1.93M

+3.24%

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 6.62, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.